Primary cutaneous large B-cell lymphoma of the legs: A distinct clinical pathologic entity treated with CD20 monoclonal antibody (Rituximab)

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 3, 2001, Pages 237-240

  Aboulafia, David M ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Monoclonal antibody; Non Hodgkin's lymphoma; Primary cutaneous large B cell lymphoma of leg; Rituximab; Treatment

Indexed keywords

RITUXIMAB;

AGED; ARTICLE; B CELL LYMPHOMA; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; FOLLOW UP; HUMAN; LEG DISEASE; MALE; NONHODGKIN LYMPHOMA; PROGNOSIS; SKIN LYMPHOMA; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LEG; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL; MALE; SKIN NEOPLASMS;

EID: 0034994062     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200106000-00005     Document Type: Article

References (18)

1. Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis
2. Treatment of multifocal primary cutaneous B-cell lymphoma: A clinical follow-up study of 29 patients
3. Karnofsky lecture: Immunotherapy of lymphoma
4. Apoptosis of malignant B cells by ligation of CD20 with monoclonal antibodies
5. EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer
6. Clinical manifestations, staging, and treatment of non-Hodgkin's lymphoma
7. Primary cutaneous B-cell lymphoma: A unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83 cases
8. Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: A clinical follow-up study of 55 patients treated with radiotherapy and polychemotherapy
9. Primary cutaneous lymphomas other than mycosis fungoides
10. EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer
11. Four varied cases of intravascular lymphomatosis and a literature review
12. Primary cutaneous large cell lymphomas. Morphologic, immunophenotypic, and clinical features of 20 cases
13. bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related
14. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
15. Use of rituximab, the new FDA-approved antibody
16. Efficacy controls and long-term follow-up of patients (PTS) treated with rituximab for relapsed or refractory, low-grade or follicular (RLG/F) NHL
17. Future strategies toward the cure of indolent B-cell malignancies. New biologic therapies